Latest / 360 with Katie Woolf / Uni of Adelaide Professor in Vaccinology Helen Marshall meningococcal study

Transcript

Uni of Adelaide Professor in Vaccinology Helen Marshall meningococcal study · 360 with Katie Woolf

• 0:00
  Speaker 1: But we do know and you will recall on many
• 0:03
  Speaker 1: occasions we have spoken to the absolutely amazing Sally Lawrence
• 0:08
  Speaker 1: and her family about the loss of their little girls, Skyler. Now,
• 0:13
  Speaker 1: she was only thirty three months old when a manager
• 0:15
  Speaker 1: cockle infection ended her young life. We've spoken to that
• 0:20
  Speaker 1: family on numerous occasions. What they have done with their
• 0:23
  Speaker 1: initiative share a Chino with Skyler has been nothing short
• 0:27
  Speaker 1: of amazing. But they have also really done quite a
• 0:30
  Speaker 1: bit of work to ensure well that there was research
• 0:35
  Speaker 1: and that there is some studies into this illness manager cockle. Now,
• 0:41
  Speaker 1: this manager Cockle study is currently underway. And joining me
• 0:44
  Speaker 1: on the line to tell us a little bit more
• 0:45
  Speaker 1: from the University of Adelaide Professor in vaccine ology, Helen Marshall.
• 0:52
  Speaker 1: Good morning to you, Helen. Let me just try that again.
• 0:56
  Speaker 1: Good morning again, Helen. How are you.
• 0:59
  Speaker 2: Very well and thanks very much for having me on today.
• 1:02
  Speaker 1: Yeah, thanks so much for your time, Helen. Tell us
• 1:04
  Speaker 1: a little bit more about this research and where it's at.
• 1:09
  Speaker 2: Yeah, Well, we started the study. It's called it be
• 1:12
  Speaker 2: part of an MP studies because you know, we're providing
• 1:15
  Speaker 2: a mini copp will be that scene through all fourteen
• 1:18
  Speaker 2: to nineteen year olds across the Northern territory. So we're
• 1:21
  Speaker 2: really working with MP Health, with government with a stand
• 1:26
  Speaker 2: with Aboriginal community control organizations to make sure that every
• 1:29
  Speaker 2: fourteen to nineteen year old has that accessed through the
• 1:32
  Speaker 2: Minida cropp will be vaccine through the study. So this
• 1:35
  Speaker 2: is the license recommended that scene that is already funded
• 1:39
  Speaker 2: by the come Wealth government for Aboriginal baby because of
• 1:43
  Speaker 2: their higher risk of Minida copp wi B to D.
• 1:46
  Speaker 2: But true the study where we're trying to acsess how
• 1:49
  Speaker 2: well vaccine works and detecting against the mini coppill B
• 1:52
  Speaker 2: to ds in this age group and also whether it
• 1:55
  Speaker 2: can reduce courage and also whether it's got cost protection
• 1:58
  Speaker 2: against gonna rear. So it's a really important study in
• 2:02
  Speaker 2: thinking how we can best protect our young people from
• 2:06
  Speaker 2: mininga coppy's these particularly.
• 2:08
  Speaker 1: And where are things out at the moment with the study,
• 2:11
  Speaker 1: how much longer is it due to go for.
• 2:15
  Speaker 2: We've started back in March twenty twenty one and as
• 2:19
  Speaker 2: you can imagine, it's been challenging with COVID of course
• 2:26
  Speaker 2: being obviously making everyone very busy and importantly getting vaccinated
• 2:31
  Speaker 2: COVID vaccine. But the recruitment to this study, of enrollment
• 2:34
  Speaker 2: in this study has been a bit slower than we
• 2:36
  Speaker 2: were expecting. So we've extended this study a bit longer,
• 2:39
  Speaker 2: but we'll certainly have to wind it up next year.
• 2:43
  Speaker 1: Okay, Helen. If there is anybody out there listening, how
• 2:46
  Speaker 1: can they get involved if they are keen to.
• 2:50
  Speaker 2: There's a number of ways, and I should say we
• 2:53
  Speaker 2: now have two thousand other two thousand young people involved,
• 2:56
  Speaker 2: which is fabulous, and we've been long in the study
• 3:00
  Speaker 2: out through the schools are very much light. The school
• 3:03
  Speaker 2: organization programs the young people like the ATV that's scene
• 3:08
  Speaker 2: and the serial technics booster VAC scene that young people
• 3:12
  Speaker 2: get through this school. So we've we've provided the vacccene
• 3:16
  Speaker 2: that way. But we've also they're also clinics established and
• 3:22
  Speaker 2: I've got a group of nurses. They're doing an amazing job.
• 3:26
  Speaker 2: So appointments can be made at Harry's place or at
• 3:31
  Speaker 2: the Palmerston clinics for anyone that wants to be all
• 3:37
  Speaker 2: take brantage off of the men property that scene three
• 3:40
  Speaker 2: through the study. The only other thing is we do
• 3:43
  Speaker 2: take folks Club on the first day and our and
• 3:47
  Speaker 2: through the different complete a good brief questionnaire, but that's
• 3:50
  Speaker 2: just to see where the people actually carrying the winning
• 3:51
  Speaker 2: the topics in their stroat, which is important for us
• 3:54
  Speaker 2: to understand as well. So there's the opportunities through the clinics,
• 3:58
  Speaker 2: there's opportunities through the oporiginal commendous controlled organizations as well.
• 4:04
  Speaker 2: And so yeah, we hope because the timing of the
• 4:07
  Speaker 2: study now is limitters be coming towards the end, we
• 4:11
  Speaker 2: do hope hesitate the advantage of being to check against
• 4:13
  Speaker 2: then copy B disease. So that's that. The Karmaston clinics
• 4:18
  Speaker 2: the availability Mondays and Thursdays and at Harry Say on
• 4:22
  Speaker 2: Wednesday afternoon. There is a website information you'd want to
• 4:27
  Speaker 2: know www dot be part of itt MT or in
• 4:31
  Speaker 2: lower case dot com do AU and that's that's where
• 4:34
  Speaker 2: you find more information about how you can be involved
• 4:38
  Speaker 2: and enroll in the studies.
• 4:39
  Speaker 1: Well, we really appreciate your time this morning. Helen Marshall
• 4:43
  Speaker 1: from the University of Adelaide, Professor in vaccine ology, thank
• 4:47
  Speaker 1: you very much for having a chat with us this morning.
• 4:50
  Speaker 2: Thank you very much for the opportunity.
• 4:52
  Speaker 1: Thank you